Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Molecular imaging to guide therapy: outline
3. Anatomic vs. functional imaging
4. Functional imaging modalities
5. Positron emission tomography (PET)
6. PET/CT
7. Why radiotracer imaging?
8. Existing cancer imaging paradigm
9. FDG PET detects mammary nodal metastases
10. A new paradigm for cancer imaging
11. Imaging and targeted therapy
12. Emerging cancer imaging paradigm
13. Localize and characterize disease sites
14. Image acquisition and quantitative analysis
15. Choosing the right patients
16. ER and breast cancer endocrine therapy
17. FES: PET estrogen receptor (ER) imaging
18. Validation: ER+ vs. ER- tumors
19. PET provides estimate of ER expression
20. FES predicts response to hormonal therapy (1)
21. FES predicts response to hormonal therapy (2)
22. Imaging hypoxia
23. FMISO PET predicts outcome for GBM patients
24. Hypoxia as a target for radiotherapy planning
25. Imaging to direct hypoxia-specific treatment
26. Choosing the right drug
27. Resistance due to altered drug transport
28. Imaging P-gp activity in vivo in humans
29. FES PET measures pharmacodynamics
30. Getting the right result
31. Events in response to successful cancer therapy
32. Thymidine incorporation pathways
33. PET imaging pre- and post one cycle of Rx
34. Thymidine analogs for cell proliferation imaging
35. Early response measured by FLT PET
36. FLT brain tumor imaging to measure response
37. Bone metastasis response monitoring (1)
38. Bone metastasis response monitoring (2)
39. Change in FDG SUV correlates with response
40. FDG uptake predicts outcome of breast cancer
41. FDG PET/CT to monitor breast cancer response
42. FDG PET vs. bone scan
43. Predicting the outcome
44. Neo-adjuvant therapy - PET assessment
45. PET predicts survival after neo-adjuvant therapy
46. Molecular imaging - measuring in vivo biology
47. Changes in cancer metabolism and blood flow
48. Results: multivariate DFS
49. Flow-metabolism mismatch and poor response
50. Match predicts path CR, mismatch: early relapse
51. Metabolism-flow mismatch predicts poor outcome
52. Altered metabolism and myocardial viability
53. Glycolysis and angiogenesis
54. Future directions
55. ACRIN experimental imaging sciences committee
56. Acknowledgements: UW PET cancer P01
57. Breast cancer imaging research group
58. Acknowledgements - collaborators

Topics Covered

• Anatomic vs. functional imaging
• Functional imaging modalities
• PET/CT
• Radiotracer imaging
• Existing cancer imaging paradigm
• A new paradigm for cancer imaging
• Imaging and targeted therapy
• Biomarker imaging
• ER expression and breast cancer endocrine therapy
• Hypoxia-specific treatment
• Biologic events in response to successful cancer therapy
• Thymidine incorporation pathways
• Bone metastasis response monitoring
• FDG PET vs. bone scan
• Neo-adjuvant therapy of breast cancer
• Molecular imaging is a tool for measuring in vivo biology
• Changes in breast cancer metabolism and blood flow predict pathologic response
• Clinical trial of novel molecular imaging probes for cancer
• ACRIN experimental imaging sciences committee

Links

Series:

• Medical Imaging

Categories:

• Cancer
• Clinical Medicine
• Diseases, Disorders & Treatments
• Methods

Therapeutic Areas:

• Oncology

Talk Citation

Mankoff, D. (2010, September 29). Clinical applications of molecular imaging: imaging to guide cancer therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 8, 2020, from https://hstalks.com/bs/1673/.

Publication History

• Published on September 29, 2010
• Reviewed on May 1, 2020

Financial Disclosures

• Prof. David Mankoff has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.